PFE Pfizer
- Official Name: PFIZER INC.
- Headquarters: 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192 US
- CEO: Albert Bourla
- Website: pfizer.com
- Key Investor: VANGUARD GROUP INC | 9.2%
- Dedicated Investor: PALACIOS WEALTH MANAGEMENT, LLC | 19.04%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 1.971 | 0.917 - (1.054) | ||
| 2025-07-21 | 2 | Won by 1.966 | (2.791) - (4.757) | ||
| 2025-07-28 | 3 | Lost by 1.837 | 0.494 - 2.331 | ||
| 2025-07-29 | 2R | Won by 4.840 | (0.749) - (5.589) | ||
| 2025-08-04 | 4 | Won by 1.423 | (1.722) - (3.145) | ||
| 2025-08-07 | 1R | Won by 1.790 | 1.159 - (0.631) | ||
| 2025-08-11 | 5 | Won by 7.298 TOTW | 6.017 - (1.281) | ||
| 2025-08-12 | 3R | Lost by 2.060 | 0.127 - 2.187 | ||
| 2025-08-18 | 6 | Lost by 1.705 | 1.820 - 3.525 | ||
| 2025-08-20 | 1R | Won by 0.486 | 0.679 - 0.193 | ||
| 2025-08-21 | 2R | Won by 1.160 | 1.163 - 0.003 | ||
| 2025-08-25 | 7 | Lost by 1.016 | 0.920 - 1.936 | ||
| 2025-09-01 | 8 | Lost by 2.214 | (1.467) - 0.747 | ||
| 2025-09-03 | 2R | Won by 0.812 | (0.810) - (1.622) | ||
| 2025-09-04 | 3R | Lost by 2.913 | (1.015) - 1.898 | ||
| 2025-09-08 | 9 | Lost by 6.423 | (0.798) - 5.625 | ||
| 2025-09-15 | 10 | Won by 3.758 | (2.622) - (6.380) | ||
| 2025-09-17 | 3R | Lost by 0.438 | 0.677 - 1.115 | ||
| 2025-09-22 | 11 | Won by 0.018 | 0.282 - 0.264 | ||
| 2025-09-29 | 12 | Lost by 0.180 | (0.781) - (0.601) | ||
| 2025-10-06 | 13 | Won by 7.277 | 7.643 - 0.366 | ||
| 2025-10-13 | 14 | Lost by 0.987 | (6.206) - (5.219) | ||
| 2025-10-20 | 15 | Won by 3.954 | (0.081) - (4.035) |
Latest News

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...

Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’
Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.

Dividend Champion, Contender, And Challenger Highlights: Week August 30
Dividend activity recap for Champions, Contenders & Challengers: dividend changes plus upcoming ex-dividend and pay dates. See more here.

BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.
Hesai Says Co Selected By NVIDIA As Lidar Partner For NVIDIA DRIVE Hyperion 10

QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk...
FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping ...

Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session.
Stay informed about the most active stocks in the S&P500 index on Wednesday's session. Discover the stocks that are generating the highest tr...